Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B Cell lymphoma

Journal of Immunotherapy

Volumn 32, Issue 6, 2009, Pages 622-631

  Betting, David J ^a   Yamada, Reiko E ^a   Kafi, Kamran ^a   Said, Jonathan ^b   Van Rooijen, Nico ^c   Timmerman, John M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

CD20; CpG; Lymphoma; Monoclonal antibody; Rituximab

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 1826; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, INBRED C3H; OLIGODEOXYRIBONUCLEOTIDES; RECEPTOR, ERBB-2; TOLL-LIKE RECEPTOR 9;

EID: 67651163872     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181ab23f1     Document Type: Article

References (52)

1. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol. 2005;23: 6421-6428.
2. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26:3603-3613.
3. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359: 613-626.
4. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443-446.
5. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-758.
6. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940-3947.
7. + cytotoxic T cells. Leukemia. 2001;15:1619-1626.
8. Dhodapkar KM, Krasovsky J, Williamson B, et al. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med. 2002;195:125-133.
9. Groh V, Li YQ, Cioca D, et al. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci USA. 2005;102:6461-6466.
10. Dhodapkar KM, Dhodapkar MV. Recruiting dendritic cells to improve antibody therapy of cancer. Proc Natl Acad Sci USA. 2005;102:6243-6244.
11. Franki SN, Steward KK, Betting DJ, et al. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood. 2008;111:1504-1511.
12. Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104: 2635-2642.
13. Davis TA, Maloney DG, Grillo-Lopez AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res. 2000;6:2644-2652.
14. Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol. 2002;117:828-834.
15. Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res. 2004;10: 2253-2264.
16. Ansell SM, Witzig TE, Kurtin PJ, et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 2002;99:67-74.
17. Kimby E. Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor [corrected]. Semin Oncol. 2002;29: 7-10.
18. Kanzler H, Barrat FJ, Hessel EM, et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007;13:552-559.
19. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007;117:1184-1194.
20. Link BK, Ballas ZK, Weisdorf D, et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother. 2006;29:558-568.
21. Friedberg JW, Kim H, McCauley M, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood. 2005;105:489-495.
22. Leonard JP, Link BK, Emmanouilides C, et al. Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res. 2007;13: 6168-6174.
23. Heckelsmiller K, Rall K, Beck S, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol. 2002;169:3892-3899.
24. Sharma S, Karakousis CP, Takita H, et al. Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors. Biotechnol Lett. 2003;25: 149-153.
25. Lonsdorf AS, Kuekrek H, Stern BV, et al. Intratumor CpG- oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol. 2003;171:3941-3946.
26. Furumoto K, Soares L, Engleman EG, et al. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest. 2004;113:774-783.
27. Sharma S, Dominguez AL, Hoelzinger DB, et al. CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged. Cancer Immunol Immunother. 2008;57:549-561.
28. Li J, Song W, Czerwinski DK, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007;179:2493-2500.
29. Brody J, Ai WZ, Czerwinski D, et al. Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: preliminary results of a phase II trial of intra-tumoral CpG 7909 (abstract 3003). J Clin Oncol. 2008;26(suppl):15s, 132a.
30. Bergman Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol. 1977;7:413-417.
31. Golay J, Cittera E, Di Gaetano N, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica. 2006;91:176-183.
32. Mineo JF, Scheffer A, Karkoutly C, et al. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice. Invest Ophthalmol Vis Sci. 2008;49:4738-4745.
33. van Ojik HH, Bevaart L, Dahle CE, et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res. 2003;63:5595-5600.
34. Wooldridge JE, Ballas Z, Krieg AM, et al. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997;89:2994-2998.
35. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174:83-93.
36. van Rooijen N, van Nieuwmegen R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res. 1984;238:355-358.
37. Miller G, Bleier JI, Antonescu C, et al. Natural killer cell depletion confounds the antitumor mechanism of endogenous IL-12 overexpression. Int J Cancer. 2004;110:395-402.
38. Minard-Colin V, Xiu Y, Poe JC, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fcgamma RI, Fcgamma R III, and Fcgamma R IV. Blood. 2008;112:1205-1213.
39. Betting DJ, Kafi K, Abdollahi-Fard A, et al. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior anti-tumor immunity against B cell lymphomas. J Immunol. 2008;181:4131-4140.
40. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
41. Neeson P, Paterson Y. A new multi-parameter flow cytometric assay for monitoring lymphoma growth and spread in a preclinical murine model for human lymphoma. Cytometry A. 2004;60:8-20.
42. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxy-nucleotides. Clin Cancer Res. 2005;11:1490-1499.
43. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc Receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199: 1659-1669.
44. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817-826.
45. Pohajdak B, Gomez J, Orr FW, et al. Chemotaxis of large granular lymphocytes. J Immunol. 1986;136:278-284.
46. Bottazzi B, Introna M, Allavena P, et al. In vitro migration of human large granular lymphocytes. J Immunol. 1985;134: 2316-2321.
47. Ramos OF, Kai C, Yefenof E, et al. The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments require the availability of the iC3b receptor (CR3) on the effectors. J Immunol. 1988;140:1239-1243.
48. Wahlin B, Perlmann H, Perlmann P, et al. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments. J Immunol. 1983;130:2831-2836.
49. Moga E, Alvarez E, Canto E, et al. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol. 2008;36: 69-77.
50. Tutt AL, French RR, Illidge TM, et al. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J Immunol. 1998;161:3176-3185.
51. Tutt AL, O'Brien L, Hussain A, et al. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol. 2002;168:2720-2728.
52. Ahuja A, Shupe J, Dunn R, et al. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol. 2007;179: 3351-3361.